🇺🇸 PF-06821497 in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 3
Most-reported reactions
- Hypokalaemia — 1 report (33.33%)
- Myelodysplastic Syndrome With Excess Blasts — 1 report (33.33%)
- Second Primary Malignancy — 1 report (33.33%)
PF-06821497 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is PF-06821497 approved in United States?
PF-06821497 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for PF-06821497 in United States?
Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.